KATHERINE BARNARD: Open Payments
NPI 1407472350 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$350 in 17 payments from 13 companies in 2025. Trend: 2023 $74 · 2024 $99 · 2025 $350
Food & beverage: $350
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 2 | $81 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| Aveo Pharmaceuticals, Inc. | 2 | $35 |
| GlaxoSmithKline, LLC. | 2 | $32 |
| TerSera Therapeutics LLC | 1 | $31 |
| JAZZ PHARMACEUTICALS INC. | 1 | $18 |
| ABBVIE INC. | 1 | $18 |
| Boston Scientific Corporation | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
| Incyte Corporation | 1 | $15 |
Products named: KISQALI, KEYTRUDA, FOTIVDA, Zoladex, ZEPZELCA, VENCLEXTA, SpaceOAR VUE System - 10mL, JEMPERLI.
Industry payments across NE — which companies pay providers there.
